Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Gains from Investment Securities (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Gains from Investment Securities for 9 consecutive years, with -$8.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 657.56% to -$8.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$772000.0, a N/A change, with the full-year FY2025 number at -$772000.0, changed N/A from a year prior.
  • Gains from Investment Securities was -$8.9 million for Q4 2025 at Denali Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.9 million in Q2 2025 to a low of -$8.9 million in Q4 2025.
  • A 5-year average of -$59384.6 and a median of $2000.0 in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 29550.0% in 2024, then plummeted 657.56% in 2025.
  • Denali Therapeutics' Gains from Investment Securities stood at -$2000.0 in 2021, then surged by 2650.0% to $51000.0 in 2022, then plummeted by 107.84% to -$4000.0 in 2023, then plummeted by 29350.0% to -$1.2 million in 2024, then tumbled by 657.56% to -$8.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Gains from Investment Securities are -$8.9 million (Q4 2025), $1.4 million (Q3 2025), and $3.9 million (Q2 2025).